Login / Signup

Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis.

Francesca PalandriDaniela BartolettiAlessandra IurloMassimiliano BonifacioElisabetta AbruzzeseGiovanni CaocciElena M ElliGiuseppe AuteriMario TiribelliNicola PolverelliMaurizio MiglinoFlorian H HeidelAlessia TieghiGiulia BenevoloEloise BeggiatoCarmen FavaFrancesco CavazziniNovella PuglieseGianni BinottoCostanza BosiBruno MartinoMonica CrugnolaEmanuela OttavianiGiorgia MicucciMalgorzata M TrawinskaAntonio CuneoMonica BocchiaMauro KramperaFabrizio PaneRoberto M LemoliDaniela CilloniNicola VianelliMichele CavoGiuseppe A PalumboMassimo Breccia
Published in: Cancer (2022)
Personalized approaches beyond RUX monotherapy may be useful in PB-4 and particularly in PB-9 patients.
Keyphrases
  • end stage renal disease
  • heavy metals
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • peritoneal dialysis
  • type diabetes
  • clinical trial
  • risk assessment